Evidence map›Paper›PMID 33282092›Full record

ArticleThe Pan African medical journal2020

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.

Julius July, Diana Patricia, Pricilla Yani Gunawan, Handrianto Setiajaya, Teridah Ernala Ginting, Teguh Pribadi Putra, Zerlina Wuisan, Dini Budhiarko, Najmiatul Masykura, Gintang Prayogi and 3 more

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Julius JulyDepartment of Neurosurgery, Medical Faculty of Universitas Pelita Harapan, Neuroscience Centre of Siloam Hospital Lippo Village, Tangerang, Indonesia.
Diana PatriciaDepartment of Pathology, Medical Faculty of Universitas Pelita Harapan, Neuroscience Centre of Siloam Hospital Lippo Village, Tangerang, Indonesia.
Pricilla Yani GunawanDepartment of Neurology, Medical Faculty of Universitas Pelita Harapan, Neuroscience Centre of Siloam Hospital Lippo Village, Tangerang, Indonesia.
Handrianto SetiajayaDivision of Neurosurgery, Department of Surgery, Rumah Sakit Pusat Angkatan Darat Gatot Subroto, Jakarta, Indonesia.
Teridah Ernala GintingMochtar Riady Institute for Nanotechnology and Medical Science group, Universitas Pelita Harapan, Lippo Village, Tangerang, Indonesia.
Teguh Pribadi PutraStemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia.
Zerlina WuisanStemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia.
Dini BudhiarkoStemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia.
Najmiatul MasykuraStemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia.
Gintang PrayogiStemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia.
Ahmad Rusdan UtomoStemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia.
Steven TandeanDepartment of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Haji Adam Malik General Hospital, Medan 20155, Medan, Indonesia.
Michael Lumintang LoeDepartment of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Haji Adam Malik General Hospital, Medan 20155, Medan, Indonesia.
PT Bio Farma (Indonesia) · IDPelita Harapan University · IDUniversitas Sumatera Utara · IDGatot Soebroto Army Hospital · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionthe objective was to evaluate the impact of IDH1 R132H mutation, MGMT methylation and PD-L1 expression in high grade glioma that received standard therapy (surgery, radiation and chemotherapy) to overall survival (OS).

methodsthis is a retrospective study of 35 high grade glioma cases. Genotyping of IDH1 gene alteration on the mutation hotspot R132 (Sanger sequencing method with Applied Biosystems 3500 Genetic Analyzer), EZ DNA Methylation-Gold kit (Zymo Research) is used to study the methylation, Cell line BT549 (ATCC HTB-122) and HCT-116 (ATCC CCL-247) were used as unmethylated control and partially methylated control respectively. Anti-human PD-L1 antibody clone E1L3N

resultsanaplastic astrocytoma cases had more MGMT promoter methylation (50%) than glioblastoma multiforme (GBM) (20%), more IDH1 R132H mutation (42%) than GBM (4.3%). Immunohistochemistry tumor proportion score method (TPS) identified 17% and 8.7% were PD-L1 positive in AA and GBM groups, respectively. Cases with IDH1 R132H mutation and MGMT methylation still showed better OS although with high PD-L1 expression.

conclusionIDH1 R132H mutation and MGMT methylation were good prognostic markers. High expression of PD-L1 apparently might not indicate poor overall survival in the presence of IDH1 R132 mutation and MGMT methylation.

Indexed as

AdolescentAdultAgedAstrocytomaB7-H1 AntigenDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleGlioblastomaHumansIsocitrate DehydrogenaseMaleMiddle AgedMutationPrognosisB7-H1 AntigenCD274 protein, humanDNA Modification MethylasesDNA Repair EnzymesIDH1 protein, humanIsocitrate DehydrogenaseMGMT protein, humanTumor Suppressor Proteinsanaplastic astrocytomaglioblastoma multiformeIDH1 mutationMGMT methylationPD-L1

Identifiers

PMID33282092
PMCPMC7687483
OpenAlexW3080176834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.